Two symbols in the periodic table of elements condense the career and life of wang yingmei, chairman of Zhejiang Yongtai Technology Co.,Ltd.

In 1999, wang yingmei, who loves chemical industry and has a strong personality, started her own business and founded Zhejiang Yongtai Technology Co., ltd. with the dream of "earning 100,000 yuan". According to the periodic table of elements, she found the element of "fluorine" and accurately predicted that "fluorine" would have a great future, with immeasurable industrial space and commercial value.

Ten years later, yongtai technology completed the a-share listing; Twenty years later, always too technology has developed into a complete product line, the production scale of the worlds leading fluorobenzene fine chemicals manufacturers, business chain vertically extends to medicine, agricultural chemicals, electronic chemicals and new energy li-ion battery materials, and other innovative chemical industry, more than 80% products are exported to Europe and the United States and Japan, supply Merck, Germany Merck, basf, bayer, such as the world 500 strong enterprises. Wang yingmei has become a magnificent blooming sonorous rose in Chinas chemical industry.

In the spring of 2019, wang yingmei, who has been running her own business for 20 years, appeared on "face the boss" of Shanghai securities news. She talked about her hard entrepreneurial process, new business progress in medicine and electronics, future development plan and "mom-and-pop" management mode.

Close to the end of recording, the host suddenly asked wang yingmei, its business to the periodic table of an element symbol and start, can also be compared with another element?

She thought about it for a moment and then replied, "my choice is probably hydrogen, because hydrogen is easy to get, its an element thats everywhere in nature, its found in water, it can be broken down. Hydrogen is the most common chemical element in human life. It can come and go very light. Do not bring any harm to mankind, left, is good."

To see the full video content, click below to read the original!

Yongtais main business is called "fluorobenzene fine chemicals". This sub-industry is located at the top of the whole fluorine chemical industry chain, with high added value and wide application range, including liquid crystal materials, medicine, pesticides, etc., which is the key industry supported and developed by the state.

In 1987, wang yingmei graduated from the school and was assigned to the fourth huangyan chemical plant. With a strong personality and a passion for chemical industry, she soon mastered the relevant technologies in the production process and became the backbone of technology from an ordinary employee.

"In 1992, when I was 28, I was still a little girl in the eyes of the factory director. I asked him several times to do some new products in the lab, and he just interrupted me and said, you just do your own work, and if you do well, we will promote you. but I didnt want to promote you, I just wanted to do more development, so I felt upset all the time. At the time, I was in the technical department, and I thought it was useless. Then you want to do something for yourself."

Ease and stability, entrepreneurship and hard work, is always a "double-edged sword." Think twice, wang yingmei chooses finally "go into the sea", with his 50 thousand yuan savings, set up linhai city star chemical plant with person partnership, from appoint factory director. "When they came out, they said how much money do you want to make, and I said I want to make $100,000, because my goal in life is $100,000."

Yongtai technology was founded at the beginning, the products are mainly dye intermediates. Although the product technology is mature and the profit is good, but the future market competition is fierce. Through professional market research, wang yingmei decided to carry out product transformation and upgrading. At that time, the emerging chemical product -- fine fluorine chemical industry became a breakthrough point, which was relatively early in the industry.

"Based on our understanding of chemistry and industry, we think fluorine will be a promising industry in the future." "Said wang yingmei.

Blink of an eye 20 years, wang yingmei recognized and adhere to the road of entrepreneurship. "Its all about technology. Those who have lower cost, better quality and updated products will live and live better. This is marketization. And I think fluorine is something that can bring more happiness to society, to humanity as a whole."

Since the listing, yongtai technology performance continued to grow. According to the companys 2018 earnings report, the net profit attributable to the owner of the parent company in 2018 was 462 million yuan, an increase of 153.54% over the same period last year. Revenue was 3.31 billion yuan, up 20.31% from the same period last year.

At present, yongtai technology has developed into the worlds leading manufacturer of fluorobenzene fine chemicals with complete product chain and production capacity. It is also one of the few a-share listed companies focusing on fluorobenzene fine chemicals.

Never too technology to produce a five series hundreds of fluorine benzene compounds, formed by three applications of fluorinated fine chemicals pharmaceutical chemicals, electronic liquid crystal chemicals and pesticides chemical structure as the main line of products, services in liquid crystal at home and abroad, medicine and pesticide, and other innovative chemical industry, more than 80% products are exported to Europe and the United States and Japan, products are mainly supply the world top 500 enterprises.

In the eyes of market investors, yongtai technology is currently one of the biggest investment highlights, is its pharmaceutical plate.

On the evening of February 12, yongtai technology announcement, wholly-owned subsidiary yongtai pharmaceutical through the FDA site inspection. FDA field inspection is the premise of ANDA approval. At present, yongtai pharmaceuticals first ANDA application has entered the final stage of review. If yongtai pharmaceutical is approved by ANDA successfully, it will further expand the international market and facilitate the promotion of the companys international preparation project.

It has always been the strategic goal of yongtai to sort out the development history of yongtai technology and build a vertically integrated industrial chain, and medicine is the first industrial sector to achieve a breakthrough.

Wang yingmei has explained publicly: "medicine is a permanent sunrise industry, with broad space for growth. The pharmaceutical intermediates of yongtai are all fluorine-containing products, and fluorine-containing in preparations has become a general trend at present, therefore, this is our opportunity. At the same time, the intermediate is the starting link of the whole pharmaceutical industry chain. Compared with the API, the profit margin is much lower and the market size is limited. This is a challenge for the development and expansion of yongtai. Therefore, in order to develop, yongtai must extend to the downstream, and after the opening of the industrial chain, we can make full use of our own intermediates, API advantages, quickly achieve breakthroughs in the pharmaceutical market.

Of course, this road is not easy to go, the quality of drugs is directly related to human safety and health, the production of raw materials and preparations must have a fairly standard production philosophy and production system, also must have a strong research and development as a backing, this is so many years yongtai technology has been quietly doing, in investment.

Data show that since 2005, yongtai science and technology annual research and development investment in science and technology has basically maintained at the annual output value of more than 5% level, the technology center was upgraded to "national recognized enterprise technology center".

On December 13, 2017, the invention patent "preparation method of 2,4, 5-trifluorophenylacetic acid" (its terminal product name is "citaletine") held by yongtai technology won the gold medal of Chinese patent in the 19th China patent award awarding conference. By the end of 2017, yongtai technology had applied for 101 national invention patents, authorized 70 invention patents, undertaken 7 national torch program projects and key new product projects, and 2 major projects in zhejiang province.

With the gradual enriching of products, yongtai technology has become famous in the industry and become an indispensable key link in the global medical innovation industry chain, which has been recognized by customers including international giants such as basf and Merck.

In addition to "citalide", it is the first blockbuster drug of hepatitis c in the history of human medicine, which has sales of more than 10 billion dollars in its first year on the market.

"It took gilead more than a decade to develop a new drug to cure hepatitis c. When they came to us, the product was not available yet, and they hoped that we could cooperate with them to develop and produce pentafluorophenol, a key raw material. I was very surprised, I said from the perspective of industry, you cured hepatitis c, isnt there no business in the future? They say we have to contribute to human life. Because of his words, I did it. I thought it was a great thing, even if the research and development failed. Then we succeeded. This is a major breakthrough in the history of medicine around the world." "One of the constants in this industry is constant innovation," she said. "one product can keep you innovating for a lifetime."

Beyond pharmaceuticals, yongtais business landscape continues to expand.

Build in one hundred too, Wang Ying sister led her team, paint a picture of a grand blueprint, through the capital market, endogenous development and extension of mergers and acquisitions fists, from the "small and exquisite" to the "big and strong" breakthrough, actively make strategic layout and industrial extension, to higher value-added, a broader market space medicine, agricultural chemicals, electronics and expansion of new materials.

In 2012, yongtai technology established the generic drug research and development platform yongtai pharmaceutical co., LTD. In 2014, the capacity building project of international preparation project was launched through private issuance. In 2016, it acquired the raw material medicine production platform zhejiang palm and the preparation production and marketing platform foshan palm; In 2017, it started the construction of the 180 mu API production base in yongtai palm. With the help of the capital market, yongtai technology has initially built a vertically integrated industrial chain connecting pharmaceutical intermediates, raw materials and preparations.

In 2015, the company acquired Shanghai nonghui to build an overseas trading platform for the future development of the pesticide sector. In 2017, the company acquired jiangsu subin, extending to pesticide active ingredients and preparations, thus building a vertically integrated industrial chain through pesticide intermediates, active ingredients and preparations.

At the same time, the company also actively innovates in the field of new materials. In addition to liquid crystal products, the company aims at emerging industries and achieves breakthroughs and layout of new materials such as CF photoresist, OLED key materials and lithium battery electrolyte.

"CF photolithography adhesive currently has high market attention. I remember when I went to communicate with them, I thought this product is suitable for us to make. We can change the formula in chemistry, because we understand synthesis." Wang yingmei further said that after the product passed the customers certification and acceptance, it can be mass production. "But we still need to do continuous research and development to meet the requirements of generation 8 and above, especially to reduce costs and gain more market share and profits. We are now working very hard as a team on this."

It is worth mentioning that yongtai technology is the product of the joint venture of husband and wife, and the influence of "mom-and-pop store" management mode on the companys continuous operation ability has been concerned by the market.

Wang yingmei and her husband he renbao, one as the chairman, the other as the general manager. For more than 20 years, the two men, despite the wind and rain, always understand and support each other.

The husband and wife have a clear division of labor in the company, one in charge of external affairs, the other specializing in technology; They share a common direction. When they encounter difficulties, they never complain about each other. They just go forward hand in hand.

"Although we are both technical, due to the need of work, we have a division of labor, he internal, I external. He manages product design and key customers internally. Capital operations, I do." Wang yingmei further explained: "the degree of cooperation is very good at the beginning, the division of labor is very clear. But time is long, also want to have 3 rules and regulations, for example our company does not have my familys relative, also does not have his familys relative. On the whole, thanks to him, he did a good job.”

A detail is, wang yingmei recording program, he renbao has been waiting in the backstage lounge, never appeared. "I dont go out and watch her record the show. I dont want to make her nervous."